AU Patent

AU2012205289A1 — Pseudopolymorphic forms of a HIV protease inhibitor

Assigned to Janssen Sciences Ireland ULC · Expires 2012-08-09 · 14y expired

What this patent protects

New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-y (IS,2R)-3-[[(4aminophenyl)sulfonyl](isobutyl)amino]-l-benzyl-2hydroxypropylcarbamate and processes for producing them are disclosed.

USPTO Abstract

New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-y (IS,2R)-3-[[(4aminophenyl)sulfonyl](isobutyl)amino]-l-benzyl-2hydroxypropylcarbamate and processes for producing them are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012205289A1
Jurisdiction
AU
Classification
—
Expires
2012-08-09
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.